Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Chemical Agents for Microbial Control01:27

Chemical Agents for Microbial Control

Chemicals play important roles in controlling microbial growth by targeting microbial structures and functions as sanitizers, antiseptics, disinfectants, and sterilants.Alcohols are commonly used sanitizers, effectively disrupting lipid membranes, which compromises cell integrity. They are also used as antiseptics and disinfectants due to their rapid action and versatility.Phenols and their derivatives phenolics , known for denaturing proteins and disrupting cell membranes, are particularly...
Surface Active Agents01:27

Surface Active Agents

Surfactants, named for their behavior at interfaces, positively adsorb at the interfaces of two phases, reducing interfacial tension. Their versatility as emulsifiers, detergents, and foaming agents stems from this ability. Surfactants, often termed amphiphiles, share the property of amphipathy, with molecules having both hydrophilic and hydrophobic portions. The hydrophilic part is called the head, and the hydrophobic part, including an elongated alkyl substituent, forms the tail.Surfactants...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer.

Seminars in oncology·2026
Same author

Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

Future oncology (London, England)·2026
Same journal

Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Corrigendum to 'The Ninth Edition Staging Project Publications' [Journal of Thoracic Oncology (2022-2024)].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Brief Report: Proposed clinical trial guidelines based on clinicopathological heterogeneity of metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

MALDI-ToF MS Method for the Characterization of Synthetic Polymers with Varying Dispersity and End Groups
06:16

MALDI-ToF MS Method for the Characterization of Synthetic Polymers with Varying Dispersity and End Groups

Published on: October 3, 2025

Miscellaneous agents

Daniel Morgensztern1, Roy S Herbst

  • 1Department of Medicine, Division of Medical Oncology, Yale University School of Medicine and Smilow Cancer Center, New Haven, Connecticut 06520, USA. daniel.morgensztern@yale.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|November 20, 2012
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Related Experiment Videos

Last Updated: May 16, 2026

MALDI-ToF MS Method for the Characterization of Synthetic Polymers with Varying Dispersity and End Groups
06:16

MALDI-ToF MS Method for the Characterization of Synthetic Polymers with Varying Dispersity and End Groups

Published on: October 3, 2025

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019